We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+50.47%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$566M
AUM Growth
+$244M
(+76%)
Cap. Flow
+$79.7M
Cap. Flow
% of AUM
14.07%
Top 10 Holdings %
Top 10 Hldgs %
52.72%
Holding
83
New
26
Increased
22
Reduced
20
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$10.7M |
| 2 |
Sanofi
SNY
|
+$9.45M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$9.01M |
| 4 |
Pennant Group
PNTG
|
+$8.5M |
| 5 |
MDCO
Medicines Co
MDCO
|
+$7.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRN
Amarin Corp
AMRN
|
+$7.86M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$7.4M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$6.78M |
| 4 |
DexCom
DXCM
|
+$6.17M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
+$5.33M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.4% |
| 2 | Miscellaneous | 13.14% |
| 3 | Real Estate | 1.69% |
| 4 | Communication Services | 1.29% |
| 5 | Industrials | 0.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
| $51.5M | 9.09% |
+160,000
| New | +$49.3M |
|
2
GSK
GSK
$102B
| $48.6M | 8.58% |
818,468
+32,000
| +4% | +$1.78M |
|
3
The Ensign Group
ENSG
$10.1B
| $30.7M | 5.42% |
676,058
+48,903
| +8% | +$2.06M |
|
4
Danaher
DHR
$152B
| $30.3M | 5.35% |
222,337
+20,759
| +10% | +$2.62M |
|
5
Ascendis Pharma A/S
ASND
$16.3B
| $28.2M | 4.98% |
202,894
-33,498
| -14% | -$3.72M |
|
|
ZGNX
6
DELISTED
Zogenix, Inc.
ZGNX
| $25.8M | 4.56% |
495,645
-148,173
| -23% | -$6.78M |
|
|
7
Sanofi
SNY
$107B
| $22.2M | 3.92% |
441,661
+201,661
| +84% | +$9.45M |
|
|
AMRN
8
CALL
Amarin Corp
AMRN
$295M
| $21.3M | 3.76% |
49,710
+41,655
| +517% | +$15.8M |
|
|
CCXI
9
DELISTED
ChemoCentryx, Inc.
CCXI
| $20.3M | 3.58% |
+513,189
| New | +$9.01M |
|
|
AMRN
10
Amarin Corp
AMRN
$295M
| $19.6M | 3.47% |
45,780
-20,705
| -31% | -$7.86M |
|
|
BOLD
11
DELISTED
Audentes Therapeutics, Inc
BOLD
| $18.3M | 3.23% |
305,726
+52,000
| +20% | +$1.95M |
|
|
12
BioCryst Pharmaceuticals
BCRX
$2.51B
| $16.9M | 2.99% |
4,904,460
+4,250,000
| +649% | +$10.7M |
|
13
Vertex Pharmaceuticals
VRTX
$137B
| $16M | 2.82% |
73,009
+22,100
| +43% | +$4.47M |
|
14
Envista
NVST
$4.36B
| $15M | 2.65% |
506,678
+188,678
| +59% | +$5.37M |
|
|
15
Pennant Group
PNTG
$1.3B
| $12.3M | 2.17% |
+371,193
| New | +$8.5M |
|
|
MDCO
16
DELISTED
Medicines Co
MDCO
| $9.71M | 1.72% |
+114,358
| New | +$7.63M |
|
17
Sarepta Therapeutics
SRPT
$2.2B
| $9.68M | 1.71% |
+75,000
| New | +$7.57M |
|
|
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
| $9.5M | 1.68% |
310,409
+230,900
| +290% | +$6.39M |
|
19
TG Therapeutics
TGTX
$8.26B
| $8.62M | 1.52% |
776,323
+2,822
| +0.4% | +$21.5K |
|
|
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $8.01M | 1.42% |
128,748
+106,748
| +485% | +$5.07M |
|
|
MODN
21
DELISTED
MODEL N, INC.
MODN
| $7.28M | 1.29% |
207,615
+86,920
| +72% | +$2.65M |
|
22
Fate Therapeutics
FATE
$291M
| $7.06M | 1.25% |
360,656
+220,000
| +156% | +$3.49M |
|
23
AstraZeneca
AZN
$252B
| $7.01M | 1.24% |
+70,281
| New | +$6.62M |
|
|
BLUE
24
DELISTED
bluebird bio
BLUE
| $6.44M | 1.14% |
+5,666
| New | +$6.16M |
|
|
RDUS
25
DELISTED
Radius Health, Inc.
RDUS
| $6.43M | 1.14% |
318,811
-25,887
| -8% | -$629K |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q4 2019 Portfolio in Review
As of Q4 2019, Eversept Partners held 83 positions worth $566M, up 76% from $322M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Eversept Partners deployed $79.7M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.
On the sell side, the largest reduction was Amarin Corp, an estimated $7.86M trimmed.
- Eversept Partners's largest Q4 2019 buy was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.
- Eversept Partners added most to BioCryst Pharmaceuticals in Q4 2019, an estimated $10.7M increase.
- Eversept Partners's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $7.86M.
- Eversept Partners fully exited Alnylam Pharmaceuticals in Q4 2019, selling an estimated $7.4M.
- Eversept Partners's ten largest holdings make up 53% of its $566M portfolio in Q4 2019.
- Eversept Partners opened 26 new positions and closed 11 in Q4 2019.
- Eversept Partners's portfolio value rose 76% quarter-over-quarter to $566M.
Based on Eversept Partners's 13F filing for Q4 2019, filed 13 Feb 2020.